Two important bits that I noticed were:
Slide 3
"COAST enrolment complete as of Feb 2024; ShORe estimated 2Q CY2024 (96% enrolled as of 3 April 2024)"
My thoughts: So we currently have 100% and 96% trial enrolment - that's excellent and means full enrolment very soon. Some patients may be already near to or completing the 12-month trial participation and first results may be starting to come through.
Slide 30
"Concentrated prescriptions in U.S. enables potential self commercialization opportunity with lean and targeted organization"
My thoughts: Does this mean they see themselves going alone to market (without partnership?) because they can and this pathway maximises returns to OPT?
I remain very positive for my investment in OPT.
Ann: Opthea Corporate Presentation - April 2024, page-3
-
- There are more pages in this discussion • 1 more message in this thread...
You’re viewing a single post only. To view the entire thread just sign in or Join Now (FREE)
Add OPT (ASX) to my watchlist
 (20min delay)
|
|||||
|
Last
71.0¢ |
Change
0.015(2.16%) |
Mkt cap ! $874.0M | |||
| Open | High | Low | Value | Volume |
| 72.0¢ | 73.0¢ | 68.0¢ | $31.96M | 45.01M |
Buyers (Bids)
| No. | Vol. | Price($) |
|---|---|---|
| 6 | 85876 | 68.0¢ |
Sellers (Offers)
| Price($) | Vol. | No. |
|---|---|---|
| 71.5¢ | 353775 | 2 |
View Market Depth
| Last trade - 16.10pm 20/09/2024 (20 minute delay) ? |
| OPT (ASX) Chart |